1-2 of 2
Wojciech Maciej Legiec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Luděk Pour, Josep Marti Tutusaus, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Maciej Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Saad Z. Usmani
Journal: Blood
Blood (2024) 144 (Supplement 1): 362.
https://doi.org/10.1182/blood-2024-200871
Published: 2024
Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold, Meletios A. Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Maciej Legiec, Ludek Pour, Ivan Spicka, Tamas Masszi, Vadim Anatolievich Doronin, Jiri Minarik, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimir Maisnar, Gabor Mikala, Stefan Norin, Marcus Thuresson, Anna Bergan, Jakob Obermüller, Roman Hajek, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Journal: Blood
Blood (2023) 142 (Supplement 1): 2018.
https://doi.org/10.1182/blood-2023-177945
Published: 2023